Intermittent fasting improves hepatic end points in nonalcoholic fatty liver disease: A systematic review and meta-analysis
Lange M, Nadkarni D, Martin L, Newberry C, Kumar S, Kushner T
Hepatology communications · 46 citas
Etiquetas de revisión
Vínculos de autores con la industriaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Organización sin fines de lucro
- European Association for the Study of the Liver
- Autores
- Al menos un autor declara un vínculo económico con la industria
Según 1 financiador declarado y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2023-08-01 · Hepatol Commun · vol. 7 · número 8
- Editorial
- Lippincott Williams & Wilkins
- Citado
- 49 citas · más que el 91% de estudios similares · 2.5× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 44 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY-NC-ND
- Áreas de investigación
- Dietary Effects on Health · Liver Disease Diagnosis and Treatment · Alcohol Consumption and Health Effects
- Palabras clave
- intermittent fasting, non-alcoholic fatty liver disease, weight loss, anthropometric outcomes, alanine aminotransferase, aspartate aminotransferase, hepatic steatosis, liver stiffness, controlled attenuation parameter, vibration-controlled transient elastography, time-restricted eating, alternate-day fasting, 5:2 diet, religious fasting
- MeSH
- humans, weight loss, diet, adult, female, male, non-alcoholic fatty liver disease, intermittent fasting
6 autores
- Marcia Lange🇺🇸 · autor de correspondenciaIcahn School of Medicine at Mount Sinai
- Devika Nadkarni🇺🇸Icahn School of Medicine at Mount Sinai
- Lily Martin🇺🇸Icahn School of Medicine at Mount Sinai
- Carolyn A. Newberry🇺🇸Cornell University; Weill Cornell Medicine
- Sonal Rajesh Kumar🇺🇸Cornell University; Weill Cornell Medicine
- Tatyana Kushner🇺🇸Icahn School of Medicine at Mount Sinai
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background and aims
Despite NAFLD being the most prevalent liver disease globally, currently there are no FDA-approved treatments, and weight loss through caloric restriction and enhanced physical activity is the recommended treatment strategy. Intermittent fasting (IF) has been proposed as an alternative strategy with additional cardiometabolic benefits. In this systematic review and meta-analysis, we evaluated the anthropometric, biochemical, and hepatic impacts of IF in patients with NAFLD.
Methods
MEDLINE, EMBASE, Cochrane Central, and conference abstracts were searched for IF interventions in adults with NAFLD until April 2, 2023. Meta-analysis with a random effects model was used to compare pre-intervention and post-intervention changes in anthropometric, biochemical, and hepatic end points in the IF intervention group with the control group. Publication bias was assessed using Egger's test.
Results
Fourteen studies were included in the systematic review and ten in the meta-analysis (n = 840 participants, 44.64% male). Studies varied in modalities for NAFLD diagnosis, duration of IF (4-52 weeks), and type of IF (5:2 diet, modern alternate-day fasting, time-restricted eating, or religious fasting). Body weight, body mass index, and waist to hip ratio all significantly improved following fasting intervention (p< 0.05). Adults with NAFLD showed an improvement in serum alanine transaminase, aspartate aminotransferase, hepatic steatosis (controlled attenuation parameter measured by vibration-controlled transient elastography), and hepatic stiffness (measured by vibration-controlled transient elastography) after fasting intervention (p < 0.05).
Conclusions
There is limited, but moderate- to high-quality evidence to suggest that IF can improve hepatic end points and promote weight loss in adults with NAFLD. Larger randomized controlled studies with extended duration are needed to further validate our findings.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY-NC-ND).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.